All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can cytogenetics predict response to venetoclax and azacitidine in MDS?

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How can cytogenetics predict response to venetoclax and azacitidine in MDS?

How can cytogenetics predict response to venetoclax and azacitidine in MDS?

Venetoclax is an orally bioavailable BCL-2 inhibitor that has demonstrated promising efficacy in combination with azacitidine. Here, Jacqueline Garcia discusses the ongoing phase Ib clinical trial, M15531 (NCT02942290), evaluating the safety and efficacy of venetoclax + azacitidine in patients with treatment-naïve, higher-risk MDS, and subgroup analyses.

Share: